

# Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study

DIMITRIOS KARRAS, IVAYLO STOYKOV, WILLEM F. LEMS, BENTE L. LANGDAHL, ÖSTEN LJUNGGREN, ANNABEL BARRETT, J. BERNARD WALSH, ASTRID FAHRLEITNER-PAMMER, GERALD RAJZBAUM, FRANZ JAKOB, and FERNANDO MARIN

**ABSTRACT. Objective.** To describe clinical fracture rates, back pain, and health-related quality of life (HRQOL) in postmenopausal women with osteoporosis who are receiving glucocorticoids (GC), during a 36-month study of teriparatide treatment for up to 18 months, with an additional 18-month followup period when patients were receiving other osteoporosis medications.

**Methods.** A prospective, multinational, observational study. Data for clinical fractures, back pain (by visual analog scale; VAS) and HRQOL (by EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month segments and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed.

**Results.** Of 1581 enrolled women with followup data, 294 (18.6%) had antecedents of GC use. Of these, 49 (16.7%) patients sustained a total of 69 fractures during the 36-month study period. Adjusted odds of fracture were significantly decreased during the last year of followup compared with the first 6 months of teriparatide treatment: an 81% decrease in the 24 to < 30-month period ( $p < 0.05$ ), and an 89% decrease in the 30 to < 36-month period ( $p < 0.05$ ). There were significant reductions in back pain and improvements in HRQOL in both groups of GC users and nonusers.

**Conclusion.** Postmenopausal women with severe osteoporosis receiving GC, who were treated with teriparatide for up to 18 months, showed a reduced incidence of clinical fractures during the third year while receiving sequential osteoporosis treatments compared with the first 6 months, together with reduced back pain and improved HRQOL. Our results should be interpreted in the context of an uncontrolled observational study in a routine clinical setting. (J Rheumatol First Release Jan 15 2012; doi:10.3899/jrheum.110947)

## Key Indexing Terms:

GLUCOCORTICOIDS  
FRACTURE

OSTEOPOROSIS  
BACK PAIN

TERIPARATIDE  
QUALITY OF LIFE

Glucocorticoids (GC) are potent antiinflammatory and immunosuppressive agents widely used for the treatment of diseases including chronic lung disease, rheumatoid arthritis

(RA) and other connective tissue diseases, and inflammatory bowel disease and after transplantation. GC use, however, is associated with adverse effects including rapid bone loss leading to osteoporosis and an increased risk of fracture<sup>1</sup>. Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis and fractures, which may occur in 30% to 50% of patients receiving chronic GC therapy<sup>1</sup>. The mechanisms underlying GC-induced deterioration of bone quality differ from those in postmenopausal osteoporosis, and affect predominantly osteoblasts and decreased bone formation<sup>2,3</sup>. The negative effect of GC on bone quality is also reflected by the higher risk of fractures in GC users than nonusers with a similar level of bone mineral density (BMD)<sup>4</sup>, indicating that the increase in fracture risk in GC users is at least partly independent of BMD.

Teriparatide [recombinant human parathyroid hormone (1-34)] is a bone anabolic agent approved for the treatment of postmenopausal women and men with severe osteoporosis who are at high risk of fracture. Evidence from a randomized, double-dummy, active-controlled trial showed that teriparatide treatment of men and women with GIO resulted in

From the Veterans Administration Hospital, Athens, Greece; Department of Medical Research, Eli Lilly and Company, Brussels, Belgium; VU University Medical Centre, Amsterdam, The Netherlands; Aarhus University Hospital, Skejby, Denmark; Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Lilly Research Centre, Windlesham, UK; Trinity College, Dublin, Ireland; Medical University, Graz, Austria; Hôpital St. Joseph, Paris, France; and Julius-Maximilians-Universität, Würzburg, Germany.

The EFOS study is funded by Eli Lilly and Company.

D. Karras, MD, Veterans Administration Hospital; I. Stoykov, MD, PhD, Lilly Research Centre; W.F. Lems, MD, PhD, Professor, VU University Medical Centre; B.L. Langdahl, MD, PhD, DMSc, Aarhus University Hospital; Ö. Ljunggren, MD, PhD, Uppsala University Hospital; A. Barrett, BSc (Hons), Lilly Research Centre; J.B. Walsh, MB, FRCPI, Trinity College; A. Fahrleitner-Pammer, MD, Medical University; G. Rajzbaum, MD, Hôpital St. Joseph; F. Jakob, MD, Julius-Maximilians-Universität; F. Marin, MD, PhD, Lilly Research Centre.

Address correspondence to Prof. Dr. D. Karras, Department of Rheumatology, Veterans Administration Hospital, Kallidromiou 50, 11473 Athens, Greece. Accepted for publication October 27, 2011.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2012. All rights reserved.

greater gains in lumbar spine BMD and fewer new vertebral fractures, compared with alendronate therapy, after 18 and 36 months of treatment<sup>5,6</sup>. Although randomized controlled trials (RCT) are considered the “gold standard” for evaluating drug efficacy, the design of such studies limits the generalizability of their findings to everyday clinical practice<sup>7</sup>. Therefore, the conclusions of RCT can be complemented by observational studies, because their findings may have wider applicability to the patient population treated in regular clinical practice.

The effectiveness of teriparatide in regular clinical practice has been evaluated in the European Forsteo Observational Study (EFOS), a 36-month prospective observational study in the outpatient setting, designed to evaluate fracture outcomes, back pain, and health-related quality of life (HRQOL) in postmenopausal women with severe osteoporosis<sup>8</sup>. The aim of our predefined analysis was to describe the baseline characteristics, fracture outcomes, back pain, and HRQOL in the subgroup of EFOS patients who were concomitantly treated with GC at any time during the study (i.e., at baseline or at any time during the 36-month followup). We describe these outcomes both during active treatment with teriparatide for up to 18 months and in the subsequent 18-month followup period after teriparatide was discontinued, when most patients were receiving other osteoporosis medications.

The changes in clinical fracture risk, back pain, and HRQOL during the up to 18-month teriparatide treatment period and the 18-month followup period for the total study cohort have been reported previously<sup>9,10</sup>.

## MATERIALS AND METHODS

**Patients.** Postmenopausal women with a diagnosis of osteoporosis who were about to initiate teriparatide treatment according to the clinical judgment and usual practice of the participating physicians were enrolled in EFOS, a multicenter, prospective, observational study conducted in 8 European countries (Austria, Denmark, France, Germany, Greece, Ireland, The Netherlands, and Sweden). Participating physicians specialized in the treatment of osteoporosis and its complications. Teriparatide treatment (20 µg once daily by self-administered subcutaneous injection; Forsteo, Eli Lilly, Windlesham, UK) was initiated at the baseline visit. Patients were followed for the duration of their teriparatide treatment, which they could discontinue at any time, with followup visits at 3, 6, 12, and up to 18 months after initiation of teriparatide. Patients were asked to return for 2 additional visits at about 6 and 18 months after discontinuing teriparatide treatment.

Patients were excluded from the study if they were currently being treated with an investigational drug or procedure, or had any contraindications as described in the teriparatide product label<sup>11</sup>. There were no further restrictions regarding patient selection. All study participants provided written informed consent prior to enrollment and were able to withdraw at any time without any consequences in their medical attention. The study was approved by local ethics committees or review boards, depending on local requirements, and was conducted from April 2004 (first patient enrolled) until February 2009 (last patient completed) in accord with the ethical standards of the Declaration of Helsinki. The study design and characteristics of the EFOS patient population have been described in detail<sup>8</sup>.

**Assessments.** Patient demographic characteristics, risk factors for osteoporosis and falls, drugs related to the risk of osteoporosis (including GC), and disease status were recorded at the baseline visit<sup>8</sup>. The number and type of previous and current medications for the treatment of osteoporosis were record-

ed. Diagnosis of osteoporosis was based upon axial or peripheral dual x-ray absorptiometry measurements of BMD and was confirmed following review of medical reports by the treating physician. Incident clinical vertebral and nonvertebral fragility fractures during the observational period were diagnosed and confirmed by review of the original radiographs and/or the radiology or surgical reports at the investigational site. A new or worsened clinical vertebral fracture was defined as the presence of a confirmed radiographic vertebral fracture associated with signs and/or symptoms suggestive of vertebral fracture(s)<sup>12</sup>.

Back pain was self-assessed by patients at each study visit using a 100-mm visual analog scale (VAS), ranging from 0 = no back pain to 100 = worst possible back pain. Patients also completed a back pain questionnaire that recorded the frequency and severity of back pain, limitations of activities, and days in bed due to back pain in the previous month<sup>9</sup>.

HRQOL was measured at each visit using the European Quality of Life Questionnaire (EQ-5D)<sup>13</sup>, where patients assess their perceived overall health status on a VAS (EQ-VAS) that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state), and classify their own health status according to 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is scored on a 3-point scale (no problems, some problems, or extreme problems). The Health State Value (HSV) was calculated from the 5 EQ-5D dimensions using the UK scoring algorithm to allow comparisons among countries<sup>14</sup>.

**Statistical analysis.** For data analyses, the total study cohort included all patients with a baseline visit and at least 1 followup visit. The post-teriparatide cohort included those patients who discontinued teriparatide at any time between baseline and 18 months and had at least 1 post-teriparatide followup visit. Patients were categorized as being GC users or nonusers. Patients in the GC user group were those who were taking GC at the baseline visit or at any time during the study.

Descriptive statistics, such as frequencies, percentages, means, SD, and ranges, were used to describe the GC user and nonuser groups. Between-group comparisons were made using chi-square or Fisher's exact tests (categorical variables) or the Kruskal-Wallis test (continuous variables).

The number of fractures occurring in GC users and nonusers was summarized in 6-month periods. For each group, a logistic regression with repeated measures was used to assess the change in number of patients with 1 or more fractures over time<sup>15,16</sup>, giving an analysis of the odds of 1 or more fractures. Patients were included in the model at all observed periods, regardless of whether they had experienced a fracture during a previous period. The repeated observations of each patient were assumed to be related, but no further assumptions were made about the relationship. Unadjusted and adjusted analyses were performed that included age, prior bisphosphonate use, and fracture in the last 12 months before starting teriparatide. Contrasts were made between the odds of fracture in the first 6 months of treatment (0 to < 6 months) and each subsequent 6-month interval.

Back pain and HRQOL were summarized over the teriparatide treatment period and after teriparatide discontinuation for the GC user and nonuser groups. Changes in back pain VAS from baseline were analyzed using a mixed model of repeated measures (MMRM), adjusting for back pain VAS at baseline, number of previous fractures, age, diagnosis of RA, duration of previous bisphosphonate therapy, and history of fracture in the 12 months before entering the study. Variables analyzed using the sign test were the number of patients reporting an improvement, no change, or worsening from baseline in the severity of back pain, frequency of back pain, and limitation of activities due to back pain. The median change from baseline in the number of days in bed due to back pain was analyzed using the Wilcoxon signed-rank test.

A similar MMRM was used to assess the change from baseline in EQ-VAS, including its baseline value. The number of patients reporting an improvement, no change, or worsening from baseline in each of the 5 EQ-5D domains was analyzed using the sign test. Changes from baseline in EQ-5D HSV were assessed using the Wilcoxon signed-rank test because this parameter has a nonparametric distribution.

## RESULTS

**Patient disposition and characteristics.** A total of 1649 postmenopausal women were enrolled in EFOS, and 1581 had a baseline visit and at least 1 postbaseline visit (the total study cohort). Of these 1581 patients, 294 (18.6%) were GC users and 1287 (81.4%) were GC nonusers. Figure 1 shows the patient disposition over the course of the study for GC user and nonuser groups.

The demographic and baseline characteristics of the GC users and nonusers are summarized in Table 1. Compared with the GC nonuser group, the GC user group was younger, had a higher frequency of surgical menopause, a higher lumbar spine BMD T score, a higher frequency of previous bisphosphonate use, and more frequent need to use their arms when standing up from a chair (Table 1). In addition, a significantly higher percentage of patients in the GC user group had RA, chronic obstructive pulmonary disease, or chronic hepatopathy, and were taking concomitant chronic medications such as antihypertensives, benzodiazepines, antiarrhythmics and antidepressants (Table 1). At baseline, the GC user group had a lower HRQOL as indicated in a significantly lower mean EQ-VAS and median EQ-HSV compared with the GC nonuser group (Table 1).

*Teriparatide treatment and osteoporosis medications after*

*teriparatide treatment.* The median duration of teriparatide treatment was similar in the GC user and nonuser groups: 545 days (Q1, Q3: 503, 554) and 542 days (Q1, Q3: 520, 555), respectively. Persistent use of calcium and vitamin D throughout teriparatide treatment was reported by 74.7% of the GC users and 68.2% of GC nonusers.

After teriparatide was discontinued, there were 156 GC users and 753 GC nonusers in the post-teriparatide cohort. The majority of GC users took osteoporosis medication after teriparatide (n = 149, 95.5%): 109 (69.9%) took any antiresorptives, mainly bisphosphonates (n = 96, 61.5%). Other antiresorptives were used much less frequently after teriparatide was discontinued and included estrogens or raloxifene (8.3%) and calcitonin (5.1%). Calcium and vitamin D were widely used after teriparatide was stopped in the GC users (89.7% and 87.8% of patients, respectively). Similarly, 706 (94.0%) of the GC nonusers took osteoporosis medication after teriparatide: 532 (70.8%) took any antiresorptives, mainly bisphosphonates (n = 478, 63.6%). The use of other antiresorptives and of calcium and vitamin D was similar to the GC users group.

*Fracture outcomes.* The incidence of fractures during teriparatide treatment (0 to < 18 months) and after teriparatide was discontinued (18 to < 36 months, when most patients were receiving other osteoporosis medications) in the GC user




Figure 1. Patient disposition, representing the total study cohort: all patients with a baseline visit and at least 1 post-baseline visit. GC: glucocorticoid.

Table 1. Baseline characteristics of glucocorticoid (GC) users and nonusers.

Characteristic	GC Users*	GC Nonusers	p
No. patients	294	1287	
Mean age, yrs (SD)	69.9 (8.2)	71.2 (8.4)	0.014
White, %	99.2	99.2	1.000
Mean body mass index (SD)	25.2 (4.3)	25.1 (4.3)	0.834
Early menopause (< 40 yrs), %	10.4	8.6	0.327
Surgical menopause, %	25.2	17.2	0.002
Nulliparous, %	11.9	13.3	0.542
Sight problems, %	48.5	44.2	0.188
Osteoporotic hip fracture in biological mother, %	19.1	21.2	0.459
Current smoker, %	14.0	12.8	0.571
Lumbar spine BMD T score	-3.11 (1.06)	-3.30 (1.18)	0.002
Prior bisphosphonate use, %	78.9	72.2	0.018
Mean no. previous fractures after age 40 yrs (SD)	3.0 (1.9)	2.9 (2.0)	0.578
Prevalence of vertebral fractures, %	85.2	88.3	0.165
≥ 4 fractures after age 40 yrs, %**	38.1	35.3	0.264
Median time since most recent fracture, yrs (IQR)	0.8 (0.2, 2.2)	0.7 (0.2, 2.5)	0.466
At least 1 fracture in 12 mo prior to study	51.7	47.6	0.208
Assist with arms when standing up from chair, %	70.0	61.8	0.009
≥ 1 fall in the last year, %	22.3	23.2	0.939
Back pain and HRQOL			
Mean back pain, VAS, mm (SD)	58.4 (27.4)	57.6 (26.4)	0.642
Mean EQ-VAS (SD)	48.8 (22.2)	52.8 (21.9)	0.005
Median EQ-HSV (IQR)	0.516 (-0.016, 0.689)	0.587 (0.088, 0.725)	< 0.001
Comorbidities (at baseline), %***			
Rheumatoid arthritis	44.9	4.4	< 0.001
Chronic obstructive pulmonary disease	22.8	5.5	< 0.001
Diabetes mellitus	6.8	5.2	0.279
Chronic liver disease	2.0	0.7	0.032
Concomitant medication (taken at study entry), %***			
Antihypertensives	42.5	36.0	0.037
Benzodiazepines	16.3	11.0	0.011
Thyroid hormones	15.3	12.9	0.271
Antidepressants	13.6	9.4	0.033
Antiarrhythmics	11.2	7.0	0.015

\* GC users were those patients receiving GC at baseline visit or at some time during the 36-month followup.

\*\* Number of patients with vertebral fractures after age 40 years was 231 (85.2%) and 999 (88.3%) in the GC user and GC nonuser groups, respectively. \*\*\* The 3 most frequent are listed plus any others that were statistically significantly different between groups. P values were calculated using chi-square or Kruskal-Wallis tests. BMD: bone mineral density; HRQOL: health-related quality of life; VAS: visual analog scale; HSV: Health State Value; IQR: interquartile range.

and nonuser groups is shown in Table 2. In the GC user group, 49 (16.7%) women sustained 1 or more fractures during the 36-month study period. Of the 69 fractures, 21 (30.4%) were vertebral, and 48 (69.6%) were nonvertebral: 38 (55.1%) of all fractures were main nonvertebral fractures at the humerus (n = 12), leg (n = 9), hip (n = 8), forearm/wrist (n = 7), and sternum/ribs (n = 2). Table 2 shows a significant decrease in the adjusted odds of fracture in the last 2 time periods compared with the first 6 months of teriparatide treatment (0 to < 6 months), i.e., the decrease was 81% in the 24 to < 30-month period and 89% in the 30 to < 36-month period after teriparatide had been discontinued.

To determine whether changes in GC use during followup may have influenced the incidence of fractures, we performed a posthoc analysis repeating the logistic regression model but adding current GC use during each 6-month period as a time-

varying covariate. As for the predefined analysis, the adjusted odds of fracture were significantly decreased (compared with the first 6-month period) during the last year of followup, i.e., there was an 88% decrease in the 24 to < 36-month period (p = 0.003) and a 94% decrease in the 30 to 36-month period (p = 0.004).

In the GC nonuser group, 159 (12.4%) women sustained 1 or more fractures during the study. Of the 189 fractures, 66 (34.9%) were vertebral and 123 (65.1%) were nonvertebral; 91 (48.1%) of all fractures were main nonvertebral fractures at the forearm/wrist (n = 34), hip (n = 19), sternum/ribs (n = 17), leg (n = 12), and humerus (n = 9). Table 2 shows a significant decrease in the adjusted odds of fracture for GC nonusers at every time period, compared with the first 6 months of teriparatide treatment (0 to < 6 months).

The adjusted odds of fracture were significantly higher in



**Table 2.** Fracture incidence during teriparatide treatment (0 to < 18 months) and after teriparatide was discontinued [(18 to < 36 months) in glucocorticoid (GC) users and nonusers (total study cohort)]. The shaded section covers the period from 18 to < 36 months' followup when teriparatide had been discontinued and the majority of patients were receiving other osteoporosis medications.

Time Period, mo	N* (missing/ unknown)	No. Fractures/ 10,000 pt-yrs	Total No. Fractures	Patients with ≥ 1 Fracture, n (%)**	Odds of Fracture*** (95% CI)	OR***† (95% CI)	p
<b>GC users</b>							
0 to < 6	294 (0)	1272	18	15 (5.1)	0.046 (0.027, 0.079)	—	—
6 to < 12	269 (0)	1608	21	17 (6.3)	0.058 (0.034, 0.097)	1.26 (0.66, 2.39)	0.480
12 to < 18	249 (0)	1150	14	13 (5.2)	0.047 (0.027, 0.083)	1.03 (0.48, 2.19)	0.938
18 to < 24	231 (0)	1211	13	12 (5.2)	0.047 (0.026, 0.086)	1.03 (0.46, 2.29)	0.949
24 to < 30	204 (0)	213	2	2 (1.0)	0.009 (0.002, 0.034)	0.19 (0.04, 0.83)	0.028
30 to < 36	179 (0)	120	1	1 (0.6)	0.005 (0.001, 0.003)	0.11 (0.01, 0.79)	0.028
Total	294 (0)		69	49 (16.7)			
<b>GC nonusers</b>							
0 to < 6	1287 (5)	1085	68	61 (4.7)	0.043 (0.033, 0.057)	—	—
6 to < 12	1206 (2)	637	37	34 (2.8)	0.025 (0.018, 0.036)	0.58 (0.38, 0.88)	0.012
12 to < 18	1122 (1)	533	29	28 (2.5)	0.022 (0.015, 0.033)	0.51 (0.32, 0.81)	0.004
18 to < 24	1040 (2)	473	23	22 (2.1)	0.019 (0.012, 0.030)	0.44 (0.27, 0.72)	0.001
24 to < 30	905 (4)	426	18	16 (1.8)	0.016 (0.010, 0.026)	0.37 (0.21, 0.64)	< 0.001
30 to < 36	812 (0)	373	14	12 (1.5)	0.013 (0.007, 0.024)	0.30 (0.16, 0.56)	< 0.001
Total	1287 (5)		189	159 (12.4)			

\* Number of patients included in the observation (number of patients with fracture data missing or unknown at this observation). \*\* As some patients experienced a fracture more than 1 time period, the total was not the sum of patients with a fracture in each period. \*\*\* Model adjusted by age, prior bisphosphonate use, and fracture in last 12 months before starting teriparatide. † Compared with 0 to < 6-month period.

the GC user group at 6 to < 12 months (OR 2.26, 95% CI 1.20–4.18,  $p = 0.007$ ), 12 to < 18 months (OR 2.12, 95% CI 1.08–4.15,  $p = 0.029$ ), and 18 to < 24 months (OR 2.48, 95% CI 1.20–5.10,  $p = 0.014$ ), compared with the GC nonuser group.

Table 3 summarizes the incidence of clinical fractures after teriparatide discontinuation in the GC users and nonusers (the post-teriparatide cohort). There was a significant reduction in the clinical fracture rates during the last 12 months of followup for GC users only.

A posthoc analysis repeating the logistic regression model but adding current GC use during each 6-month period as a time-varying covariate in the GC user group gave results similar to those in Table 3. Compared with the first 6 months after

teriparatide was discontinued (0 to < 6 months), there was a significant decrease in the adjusted odds of fracture at 6 to < 12 months (OR 0.08, 95% CI 0.01–0.57,  $p = 0.012$ ) and 12 to < 18 months (OR 0.07, 95% CI 0.01–0.46,  $p = 0.005$ ) after teriparatide discontinuation.

**Back pain.** Figure 2 shows significant reductions in adjusted mean back pain VAS scores from baseline at each postbaseline visit in both the GC user and nonuser groups, with no significant differences between the groups. Similar results were obtained when the model was repeated including GC use as a time-varying covariate (data not shown). Results from the back pain questionnaire show significant reductions from baseline in back pain frequency and severity, limitations of

**Table 3.** Fracture incidence after teriparatide was discontinued in glucocorticoid (GC) users and nonusers (post-teriparatide cohort).

Time Period, mo	N*	No. Fractures/ 10,000 pt-yrs	Total No. Fractures	Patients with ≥ 1 Fracture, n (%)*	Odds of Fracture** (95% CI)	OR**† (95% CI)	p
<b>GC users</b>							
0 to < 6	156	1416	11	10 (6.4)	0.065 (0.033, 0.131)	—	
6 to < 12	152	140	1	1 (0.7)	0.006 (0.001, 0.047)	0.10 (0.01, 0.78)	0.028
12 to < 18	137	153	1	1 (0.7)	0.007 (0.001, 0.051)	0.11 (0.01, 0.83)	0.033
Total	156		13 <sup>††</sup>	11 (7.1)			
<b>GC nonusers</b>							
0 to < 6	753	427	16	14 (1.9)	0.018 (0.010, 0.031)	—	
6 to < 12	715	413	14	13 (1.8)	0.018 (0.010, 0.031)	0.98 (0.45, 2.11)	0.955
12 to < 18	666	479	15	13 (2.0)	0.019 (0.011, 0.033)	1.04 (0.49, 2.18)	0.928
Total	753		45 <sup>#</sup>	39 (5.2)			

\* As some patients experienced a fracture in more than 1 time period, the total was not the sum of patients with a fracture in each period. \*\* Model adjusted by age, prior bisphosphonate use, and fracture in last 12 months before starting teriparatide. † Compared with 0 to < 6-month interval after teriparatide was stopped. †† Four vertebral and 9 nonvertebral fractures. # Eleven vertebral and 34 nonvertebral fractures.




Figure 2. Adjusted mean change in back pain visual analog scale (VAS) from baseline during treatment and after teriparatide discontinuation in glucocorticoid (GC) users and nonusers. Model includes baseline back pain VAS score, number of previous fractures, fracture in 12 months before study entry, age, duration of previous bisphosphonate use, and diagnosis of rheumatoid arthritis. The unadjusted mean back pain VAS scores at baseline, 3, 6, 12, 18, 24, and 36 months and end of study (last observation carried forward) for the GC users were 58.4 (SD 27.4), 42.5 (SD 25.4), 37.9 (SD 25.9), 35.3 (SD 26.4), 32.8 (SD 26.1), 32.9 (SD 28.1), 31.3 (SD 27.6), and 36.9 (SD 28.8), respectively. For the GC nonuser group, the corresponding unadjusted mean scores were 57.6 (SD 26.4), 43.0 (SD 24.9), 38.4 (SD 25.3), 34.5 (SD 25.5), 31.7 (SD 25.4), 31.9 (SD 26.4), 28.8 (SD 26.0), and 32.7 (SD 26.9). Between-group difference for the unadjusted scores was significant only for end of study ( $p = 0.02$ , 2-sample  $t$  test). The unadjusted mean change from baseline to endpoint for the GC users and nonusers was  $-22.0$  (SD 34.9) and  $-24.8$  (SD 31.2), respectively. All values  $p < 0.001$  versus baseline. SE: standard error.

activities due to back pain, and number of days in bed due to back pain during teriparatide treatment in both the GC user and nonuser groups (Table 4). These changes were maintained after teriparatide was discontinued. The only differences seen between the GC user and nonuser groups were a greater change in severity of back pain and fewer days in bed due to back pain after teriparatide was discontinued in the GC nonuser group (Table 4).

**Health-related quality of life.** Figure 3 shows a significant improvement from baseline in EQ-VAS in both the GC user and nonuser groups at all postbaseline visits. The increase in EQ-VAS was significantly higher in the GC nonuser group than in the GC user group at the 12-month visit only. Results similar to those in Figure 3 were obtained when the model was repeated including GC use as a time-varying covariate (data not shown). The percentage of GC users and nonusers reporting some/extreme problems for each of the 5 EQ-5D domains is summarized in Table 5. There were significant improvements from baseline ( $p < 0.001$ , sign test) in all 5 domains during teriparatide treatment that were maintained after teriparatide was discontinued.

In the GC user group, median (Q1, Q3) HSV values were significantly increased ( $p < 0.001$ , Wilcoxon signed-rank test) from baseline at all postbaseline visits and were 0.689 (0.516, 0.796) at 18 months and 0.691 (0.516, 0.812) at 36 months. The same was seen in the GC nonuser group, where the median (Q1, Q3) HSV values were 0.725 (0.620, 0.848) and 0.760 (0.587, 1.000) at 18 and 36 months, respectively.

## DISCUSSION

The results of this subgroup analysis of the EFOS study showed that postmenopausal women with severe osteoporosis receiving GC, who were treated with teriparatide for up to 18 months in a routine clinical setting, had a reduced incidence of clinical fractures during the third year of observation, when the majority of them received subsequent treatment with calcium, vitamin D, and antiresorptive drugs. This finding was accompanied by reduced back pain and improved HRQOL during teriparatide treatment that was maintained after the drug was discontinued. The clinical characteristics of the patients enrolled in the EFOS study show that both groups of GC users and nonusers who were treated with teriparatide had

Table 4. Back pain questionnaire results for glucocorticoid (GC) users and nonusers. Total number varies for each variable due to missing data. Percentages given for each variable refer to the total number available for that variable.

	Baseline	During Teriparatide Treatment Period				After Teriparatide Discontinued		
		3 Mo	6 Mo	12 Mo	18 Mo	24 Mo	36 Mo	End of Study (LOCF) <sup>a</sup>
Frequency of back pain								
GC users, no.	291	270	260	239	232	190	174	280
Every day/almost every day, %	63.9	38.9*	31.5*	32.6*	26.3*	26.3*	24.7*	30.7*
GC nonusers, no.	1278	1190	1151	1082	1039	894	816	1239
Every day/almost every day, %	63.0	34.7*	32.6*	28.0*	25.5*	24.3*	20.2*	26.0*
Severity of back pain								
GC users, no.	276	246	235	200	191	147	137	229
Severe, %	46.0	19.1*	15.7*	16.5*	12.6*	16.3*	19.0*	21.4*
GC nonusers, no.	1205	1074	1005	892	837	700	611	976
Severe, %	45.1	18.3*	14.4*	13.0*	11.2*	12.3*†#	10.6*†#	14.2*†#
Limitation of activities <sup>b</sup>								
GC users, no.	276	245	234	200	190	149	136	229
Severe, %	43.5	21.6*	14.5*	18.5*	11.6*	15.4*	15.4*	18.8*
GC nonusers, no.	1206	1074	1004	892	841	703	613	977
Severe, %	35.9#	16.0*#	12.5*#	10.4*#	10.0*#	12.2*	11.4*	13.9*#
Days in bed due to back pain <sup>c</sup>								
GC users, no.	276	246	235	200	189	149	137	230
At least 1, %	26.8	12.2	8.9	9.0	7.4	12.1	9.5	10.4
Median (Q1, Q3) <sup>d</sup>	6 (2, 15)	4 (2, 10)‡	4 (2, 5)‡	4 (2, 6)‡	3 (1, 10)‡	5 (2, 15)‡	4 (2, 10)‡	5 (3, 10)‡
GC nonusers, no.	1203	1072	1005	890	839	701	610	975
At least 1, %	19.9	7.4	6.2	5.3	5.0	6.7	5.1	7.5
Median (Q1, Q3) <sup>d</sup>	8 (3, 20)	5 (2, 10)‡	3 (2, 6)‡	4 (2, 6)‡	3 (2, 10)‡	3 (2, 7)‡	2 (2, 4)‡†	3 (2, 6)‡†

<sup>a</sup> Missing data were handled using the last observation carried forward (LOCF) method. <sup>b</sup> Due to back pain. <sup>c</sup> In past month. <sup>d</sup> For those patients with at least 1 day in bed due to back pain during the last month. \*  $p < 0.001$  change from baseline (sign test). †  $p < 0.05$  between-group comparison for change from baseline (Cochran-Mantel-Haenszel test or Kruskal-Wallis test). ‡  $p < 0.001$  Wilcoxon signed-rank test for significance of median change from baseline (all patients; those without back pain are included as 0 days). #  $p < 0.05$  between-group comparison (Cochran-Mantel-Haenszel test).

severe osteoporosis, a highly impaired HRQOL, and were at very high risk of further fractures as indicated by their risk profiles at baseline. A high proportion of patients in both groups had previously used bisphosphonates, which was expected because bisphosphonates are routinely used as first-line treatment for postmenopausal osteoporosis. Although we did not collect the reasons for initiating teriparatide in our study, most of the treatment guidelines in the participating countries indicate that teriparatide can be used as a second-line treatment for severely osteoporotic patients who do tolerate or have contraindications to other osteoporosis medications, or who have sustained new fractures while taking other osteoporosis medications. However, in some countries teriparatide can be used as first-line therapy in patients with severe osteoporosis.

We performed a subgroup analysis based on GC use because it has been well established that treatment with GC significantly increases the risk for fragility fractures, especially in postmenopausal women<sup>17,18</sup>. Moreover, although both GIO and postmenopausal osteoporosis lead to bone loss and increased fracture risk, these bone metabolic disorders differ in their pathophysiological mechanisms<sup>2,3,19</sup>. Thus, chronic exposure to GC has various direct and indirect effects on bone tissue, with a primary effect on lowering bone formation due to inhibition of the differentiation, activity, and lifespan of the

osteoblasts and osteocytes<sup>1,3,20</sup>. In contrast, postmenopausal osteoporosis is mainly characterized by an accelerated bone turnover secondary to an increased rate of bone resorption due to osteoclast hyperactivity that is not compensated for by adequate bone formation to maintain a normal bone balance. The histomorphometric analysis of biopsies from individuals receiving GC shows a greater reduction in bone formation at the cellular and tissue level compared with that noted in postmenopausal osteoporosis<sup>21</sup>. Moreover, it has been suggested that the combination of GC therapy in osteoporotic subjects receiving longterm treatment with potent antiresorptive drugs, such as bisphosphonates, may increase the risk for atypical subtrochanteric and diaphyseal femoral fractures<sup>22,23</sup>. Based on the pathophysiology of GIO, it has been suggested that pharmacological agents that stimulate bone formation and accelerate remodeling may be a more appropriate treatment option than antiresorptive agents for patients with GIO at high risk for fracture<sup>5,24,25</sup>.

Teriparatide has a number of pharmacological effects that could counteract the main mechanisms of GC-induced bone loss. It increases the differentiation of bone lining cells and preosteoblasts into osteoblasts, enhances osteoblast function, and decreases osteoblast and osteocyte apoptosis<sup>26,27,28,29</sup>, resulting in an improvement of the microarchitectural properties of the bone and an increase in its strength<sup>30,31</sup>.




Figure 3. Adjusted mean change in European Quality of Life Questionnaire visual analog scale (EQ-VAS) from baseline during treatment and after teriparatide discontinuation in glucocorticoid (GC) users and nonusers. Model includes baseline EQ-VAS score, number of previous fractures, fracture in 12 months before study entry, age, duration of previous bisphosphonate use, and diagnosis of rheumatoid arthritis. For GC users, unadjusted mean EQ-VAS values at 0, 3, 6, 12, 18, 24, and 36 months and end of study (last observation carried forward) were 48.8 (SD 22.2), 55.7 (SD 19.2), 58.9 (SD 20.9), 59.8 (SD 22.4), 63.5 (SD 22.1), 63.6 (SD 24.5), 64.8 (SD 24.2), and 60.0 (SD 24.3), respectively. The corresponding values for the GC nonuser group were 52.8 (SD 21.9), 59.7 (SD 19.9), 62.6 (SD 19.8), 65.6 (SD 21.1), 68.3 (SD 21.1), 68.2 (SD 21.9), 69.6 (SD 22.0), and 65.9 (SD 22.9). Between-group difference for the unadjusted scores was significant at every timepoint ( $p < 0.05$ , 2-sample t test). The unadjusted mean change from baseline to endpoint was 12.1 (SD 28.7) and 12.9 (SD 26.2) in the GC user and nonuser groups, respectively. All values  $p < 0.001$  versus baseline. † $p < 0.05$  versus GC user group.

In a recent RCT in patients with GIO, Saag, *et al*<sup>5</sup> showed that 18 months of teriparatide treatment resulted in a greater increase in BMD than alendronate treatment. Significantly fewer subjects had new vertebral fractures in the teriparatide group compared with the alendronate group (0.6% vs 6.1%, respectively;  $p = 0.004$ ), while the incidence of nonvertebral fractures was similar in both groups (5.6% vs 3.7%;  $p = 0.36$ ). In the subgroup of postmenopausal women with GIO, increases from baseline in lumbar spine BMD were significantly greater in the teriparatide group compared with the alendronate group (7.8% vs 3.7%;  $p < 0.001$ )<sup>32</sup>. In addition, there were fewer new vertebral fractures in the teriparatide group (0.9% vs 5.4% in the alendronate group;  $p = 0.05$ ), and the incidence of nonvertebral fractures was similar in both groups (6.7% vs 4.2%;  $p = 0.36$ )<sup>32</sup>. On the basis of this RCT, the recently published American College of Rheumatology 2010 guidelines for the prevention and treatment of GIO now recommend teriparatide as an alternative treatment option to oral or intravenous bisphosphonates for patients at high risk of fracture<sup>33</sup>.

Observational studies can complement RCT because they provide information on the use and effectiveness of treatments in routine clinical practice. EFOS was conducted in a naturalistic setting without randomization to treatment and included

a broader range of patients than those included in the pivotal RCT with teriparatide<sup>5,34</sup>.

Although it is difficult to compare the results of this observational study with the phase III RCT of teriparatide versus alendronate in GIO<sup>5,32</sup>, our findings suggest that in routine clinical practice in the European countries represented in EFOS, teriparatide is used in patients at higher risk than the population included in the RCT<sup>5</sup>. Compared with the subgroup of postmenopausal women included in the RCT<sup>32</sup>, GC users in EFOS were older (69.9 vs 61.9 years), had a lower lumbar spine T score (−3.1 vs −2.7), and had a higher frequency of prevalent vertebral fractures (85% vs 39%). Of note, we observed that in normal clinical practice, despite the current recommendations for calcium and vitamin D supplementation in GIO<sup>35</sup>, more than one-quarter of GC users did not consistently take these supplements during teriparatide therapy.

The results of our study revealed that the rapid improvements from baseline in HRQOL and back pain during teriparatide treatment were similar in GC users and nonusers. This improvement was significant in both groups, despite the worse baseline HRQOL of the GC users. The benefits with regard to back pain and HRQOL were maintained after teriparatide was discontinued, when most of the patients received subsequent antiresorptive therapy, mainly oral bisphosphonates.



Table 5. Percentage of glucocorticoid (GC) users and nonusers reporting problems (some/extreme) in each of the EQ-5D domains. Number varies for each variable and at each timepoint due to missing data. Percentage given for each variable refers to the total number available for that variable.

	Baseline	During Teriparatide Treatment Period				After Teriparatide Discontinued		
		3 Mo	6 Mo	12 Mo	18 Mo	24 Mo	36 Mo	End of Study (LOCF) <sup>a</sup>
<b>Mobility</b>								
GC users, no.	289	264	257	238	229	186	173	265
Some/extreme problems	77.2 <sup>#</sup>	68.2 <sup>*#</sup>	60.7 <sup>*#</sup>	61.3 <sup>*#</sup>	57.2 <sup>*#</sup>	54.8 <sup>*#</sup>	53.2 <sup>*#</sup>	58.9 <sup>*#</sup>
GC nonusers, no.	1278	1161	1132	1060	1010	877	768	1155
Some/extreme problems	67.5	52.8 <sup>*</sup>	48.0 <sup>*</sup>	42.9 <sup>*†</sup>	41.0 <sup>*</sup>	40.1 <sup>*</sup>	38.8 <sup>*</sup>	44.4 <sup>*</sup>
<b>Self-care</b>								
GC users, no.	290	265	257	238	229	186	173	265
Some/extreme problems	54.1 <sup>#</sup>	43.8 <sup>*#</sup>	35.4 <sup>*#</sup>	37.0 <sup>*#</sup>	34.9 <sup>*#</sup>	34.4 <sup>*#</sup>	35.3 <sup>*#</sup>	40.8 <sup>*#</sup>
GC nonusers, no.	1272	1163	1130	1059	1012	877	770	1158
Some/extreme problems	40.9	28.4 <sup>*</sup>	25.6 <sup>*</sup>	22.3 <sup>*</sup>	22.1 <sup>*</sup>	20.9 <sup>*</sup>	22.3 <sup>*</sup>	25.6 <sup>*</sup>
<b>Usual activities</b>								
GC users, no.	290	265	257	236	229	185	173	264
Some/extreme problems	84.1 <sup>#</sup>	72.8 <sup>*#</sup>	66.5 <sup>*#</sup>	66.1 <sup>*#</sup>	61.1 <sup>*#</sup>	58.4 <sup>*#</sup>	57.2 <sup>*‡</sup>	65.2 <sup>*#</sup>
GC nonusers, no.	1273	1155	1128	1059	1011	876	768	1156
Some/extreme problems	74.9	63.2 <sup>*</sup>	55.3 <sup>*</sup>	53.0 <sup>*</sup>	48.7 <sup>*</sup>	47.3 <sup>*</sup>	48.0 <sup>*</sup>	53.6 <sup>*</sup>
<b>Pain and discomfort</b>								
GC users, no.	289	264	255	238	228	186	174	265
Some/extreme	95.8 <sup>‡</sup>	86.4 <sup>*</sup>	82.0 <sup>*</sup>	79.0 <sup>*</sup>	78.5 <sup>*‡</sup>	73.1 <sup>*‡</sup>	71.3 <sup>*‡</sup>	78.9 <sup>*#</sup>
GC nonusers, no.	1265	1159	1122	1057	1009	876	769	1154
Some/extreme	91.6	84.6 <sup>*</sup>	78.9 <sup>*</sup>	76.2 <sup>*</sup>	70.4 <sup>*</sup>	68.7 <sup>*</sup>	63.8 <sup>*</sup>	70.9 <sup>*</sup>
<b>Anxiety and depression</b>								
GC users, no.	291	264	256	238	228	186	173	264
Moderate/extreme	65.3 <sup>‡</sup>	54.9 <sup>*‡</sup>	50.4 <sup>*‡</sup>	49.6 <sup>*‡</sup>	44.7 <sup>*</sup>	47.8 <sup>*‡</sup>	41.6 <sup>*</sup>	48.9 <sup>*‡</sup>
GC nonusers, no.	1273	1161	1130	1059	1012	877	769	1157
Moderate/extreme	55.9	47.9 <sup>*</sup>	43.5 <sup>*‡</sup>	42.1 <sup>*</sup>	40.2 <sup>*</sup>	42.2 <sup>*</sup>	38.1 <sup>*</sup>	42.1 <sup>*</sup>

<sup>a</sup> Missing data were handled using the last observation carried forward (LOCF) method. \*  $p < 0.001$  change from baseline (sign test). †  $p < 0.05$  between-group comparison for change from baseline (Cochran-Mantel-Haenszel test). ‡  $p < 0.05$ , #  $p < 0.001$  between-group comparison (Cochran-Mantel-Haenszel test).

Our study has several limitations. First, the number of patients in the GC users group was rather small (294 patients, 18% of total study cohort). Second, the study was not randomized and there was no comparator group to teriparatide, so we cannot attribute observed changes in any endpoint to teriparatide treatment. Third, although the risk of fracture is related to GC dose and duration of therapy<sup>1</sup>, we did not collect quantitative data on these variables. Fourth, our method for quantifying the fracture incidence may have led to an underestimation of fractures, because only symptomatic vertebral fractures were considered, and it is well known that between 60% and 70% of spine fractures are asymptomatic. Fifth, as the information on previous and concurrent medication use was based on patient self-report, it may be subject to recall bias. In addition, the back pain results must be interpreted conservatively because we did not collect information on the use of analgesics during the study. Finally, the study included only postmenopausal women, so the findings cannot be extended to men or premenopausal women.

As the safety of teriparatide has already been established and was not an objective of this observational study, adverse events were not recorded. Investigators were reminded to report any significant adverse events to the study sponsor. All spontaneously reported adverse events have been

reported previously<sup>10</sup> and confirm that teriparatide is well tolerated.

The strengths of our study include the recruitment of a diverse range of patients, many of whom had comorbidities or were taking concomitant medications often excluded in RCT, reflecting real-life clinical practice. Other strengths are the prospective examination of clinical fractures both during teriparatide therapy and after teriparatide discontinuation, the analysis of pain and HRQOL using validated patient-completed instruments, and the adjustment for potential confounding factors in the analyses, including age, prior bisphosphonate use, and previous fracture in the 12 months before starting teriparatide.

In our study of postmenopausal women with severe osteoporosis treated with teriparatide for up to 18 months and followed for an additional 18 months in a routine setting, those who were also receiving GC, and who were therefore at even greater risk of fracture, showed a reduced incidence of clinical fractures during the third year, when most patients were receiving sequential therapy with other osteoporosis medications. These patients also reported a significant reduction in back pain and an improvement in HRQOL during the 18 months of teriparatide treatment, which was maintained for at least 18 months after teriparatide was discontinued, when the majority of patients were receiving other osteoporosis med-

ication. Our findings should be interpreted in the context of a noncontrolled observational study and the small number of GC users analyzed.

## ACKNOWLEDGMENT

The authors thank all physicians and patients participating in EFOS. The authors also thank Christine Jones, Lilly Germany, for central study coordination; Clare Barker for the development of the statistical analysis protocol and the study analysis; and Deirdre Elmhirst for helping in the preparation of the manuscript.

## REFERENCES

1. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. *Osteoporos Int* 2007;18:1319-28.
2. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality [editorial]. *Arthritis Rheum* 2007;56:3518-22.
3. Compston J. Management of glucocorticoid-induced osteoporosis. *Nat Rev Rheumatol* 2010;6:82-8.
4. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. *Arthritis Rheum* 2003;48:3224-29.
5. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med* 2007;357:2028-39.
6. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum* 2009;60:3346-55.
7. Silverman SL. From randomized controlled trials to observational studies. *Am J Med* 2009;122:114-20.
8. Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Langdahl BL, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): Postmenopausal women entering teriparatide treatment in a community setting. *Curr Med Res Opin* 2008;24:377-84.
9. Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). *Calcif Tissue Int* 2009;85:484-93.
10. Fahrleitner-Pammer A, Langdahl B, Marin F, Jakob F, Karras D, Barrett A, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). *Osteoporos Int* 2011;22:2709-19.
11. Forsteo (teriparatide). Summary of product characteristics. London: European Medicines Agency; 2011. [Internet. Accessed November 23, 2011.] Available from: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000425/human\\_med\\_000798.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000425/human_med_000798.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true)
12. Ross PD. Clinical consequences of vertebral fractures. *Am J Med* 1997;103:30S-43S.
13. Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. *Ann Med* 2001;33:337-43.
14. Szende A, Williams A, editors. Measuring self-reported population health: An international perspective based on EQ-5D. Budapest: SpringerMed; 2004.
15. Liang YK, Zeger SL. Longitudinal data analysis using generalized linear models. *Biometrika* 1986;73:13-22.
16. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
17. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ, et al. A meta-analysis of prior corticosteroid use and fracture risk. *J Bone Miner Res* 2004;19:893-99.
18. Van Staa TP, Leufkens HGM, Abenham L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. *J Bone Miner Res* 2000;15:993-1000.
19. Silverman SL, Lane NE. Glucocorticoid-induced osteoporosis. *Curr Osteoporos Rep* 2009;7:23-6.
20. Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity. *Bone* 2010;46:564-70.
21. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. *J Bone Miner Res* 2001;16:97-103.
22. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. *Bone* 2010;47:169-80.
23. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2010;25:2267-94.
24. Rizzoli R. How does teriparatide compare with alendronate for the treatment of glucocorticoid-induced osteoporosis? *Nat Clin Pract Endocrinol Metab* 2008;4:372-3.
25. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? *Arthritis Rheum* 2011;63:325-8.
26. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. *Endocrinology* 1995;136:3632-8.
27. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. *J Clin Invest* 1999;104:439-46.
28. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. *N Engl J Med* 2007;357:905-16.
29. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. *Arch Biochem Biophys* 2008;473:218-24.
30. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modelling of QCT scans in women with osteoporosis. *J Bone Miner Res* 2007;22:149-57.
31. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: Results from the EUROFOR study. *J Bone Miner Res* 2009;24:1672-80.
32. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: An analysis by gender and menopausal status. *Osteoporos Int* 2009;20:2095-104.
33. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Care Res* 2010;62:1515-26.
34. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001;344:1434-41.
35. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. *Cochrane Database Syst Rev* 2000;2:CD000952.